Urigen Pharmaceuticals Inc.

Tracy Taylor, a director of Urigen and chairman of the board of directors, serves as president and chief executive officer of Kansas Technology Enterprise Corporation, or KTEC, a private-public partnership dedicated to stimulating technology-based economic development in the State of Kansas. Mr. Taylor's extensive corporate and entrepreneurial experience has been integral to the success of KTEC. After his initial position in corporate finance at Ford Motor Company, Mr. Taylor jointed United Telecom in 1982 to work on the company's mergers and acquisitions. Less than two years later, Mr. Taylor was selected to a 12-person team that developed a business plan for what eventually became the Sprint Corporation. As Sprint grew into a Fortune 100 company, Mr. Taylor played a leadership role in the management side, serving as the treasurer of US Sprint. Mr. Taylor led the regional site selection for Sprint's World Headquarters in Overland Park, Kansas, which covers over 300 acres and holds more than 16,000 employees. Mr. Taylor graduated from Bethany College and received his M.B.A. degree from the University of Kansas. Mr. Taylor's experience in business, entrepreneurial endeavors and technology-oriented business growth place him in a position to contribute to a wide variety of boards and organizations. While Mr. Taylor has served on several boards across the state and country, his most recent contributions have been on the Enterprise Center of Johnson County, a working incubator focused on the commercialization of technology; Mid-America Manufacturing Technology Center (MAMTC); KansasBio; and Catalyst Lighting, a publicly-traded company. Mr. Taylor has served on Urigen's board of directors since December 2005.

Benjamin F. McGraw, III, Pharm.D. has served on our Board of Directors since April 2000, except for the period from November 2002 to December 2002. Dr. McGraw has been President and Chief Executive Officer since 1994, and Chairman of the Board since 1996, of Valentis, Inc., a biotechnology company. Prior to this, Dr. McGraw was Corporate Vice President for Corporate Development of Allergan. Before that, he was an equity analyst and a fund manager at Carerra Capital Management. Prior to this, he was Vice-President, Development for Marion Laboratories and Marion, Merrell Dow. Dr. McGraw received B.S. and Doctor of Pharmacy degrees from the University of Tennessee Center for the Health Sciences where he also completed a clinical practice residency.

Cynthia Sullivan , 51 , currently serves as President and Chief Executive Officer of Immunomedics (NasdaqGM: IMMU), a biopharmaceutical company focused on the development of products for cancer, autoimmune, and other serious diseases. She has been employed by Immunomedics since 1985 and has held various positions, including Executive Vice President, Chief Operating Officer, and President. Prior to joining Immunomedics, Ms. Sullivan was employed by Ortho Diagnostic Systems, Inc., a subsidiary of Johnson & Johnson. She earned a BS from Merrimack College, North Andover, Massachusetts, followed by a year of clinical internship with the school of Medical Technology at Muhlenberg Hospital, Plainfield, New Jersey, resulting in a M.T. (ASCP) certification. She completed an MS degree from Fairleigh Dickinson University where she also received her MBA. Ms. Sullivan was appointed as chairperson of the Company's audit committee.

S. Grant Mulholland, M.D., has achieved international recognition for his interest and expertise in urologic oncology and general urology over the past 30 years. Dr. Mulholland is a member of numerous urologic, oncologic and surgical organizations, including the past President of the Philadelphia Urologic and Mid-Atlantic Section of the American Urological Association. Dr. Mulholland has also authored over 180 articles, chapters and books.

S. Grant Mulholland, M.D., has achieved international recognition for his interest and expertise in urologic oncology and general urology over the past 30 years. Dr. Mulholland is a member of numerous urologic, oncologic and surgical organizations, including the past President of the Philadelphia Urologic and Mid-Atlantic Section of the American Urological Association. Dr. Mulholland has also authored over 180 articles, chapters and books. Christian Stief, M.D., is an internationally recognized scientist and practicing urologist; since 2004 he has been Professor and Chairman of the Department of Urology at the Klinikum der Ludwig-Maximilians-Universitat Munchen, the largest and one of the leading University urological centers in Europe. From 1996 through 2003 he served as Professor and Vice Chairman of the Depart of Urology at Hannover Medical School in Hannover, Germany. His main areas of interest are smooth muscle pharmacology; bladder carcinoma and reconstructive surgery. Professor Stief has published more than 200 manuscripts in peer reviewed journals and more that 50 chapters in medical textbooks.